3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
1
Interventions
Gemcitabine
9
Paclitaxel
8
Carboplatin
7
atezolizumab
6
Sunitinib
5
navitoclax
4
Topotecan
4
Irinotecan
4
Docetaxel
4
Bevacizumab
4
pazopanib
3
liposomal doxorubicin
3
cobimetinib
3
Nivolumab
3
Erlotinib Hydrochloride
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
temsirolimus
2
selicrelumab
2
plocabulin
2
envafolimab
2
darinaparsin
2
brigimadlin
2
adavosertib
2
Tablets
2
Sorafenib
2
Rifampin
2
RG7388
2
Panitumumab
2
NVP-BKM120
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumors
×
ODM-207
×
Clear all
NCT03035591
2019-10-15
BETIDES
Orion Corporation, Orion Pharma
Phase 1/2
Completed
36 enrolled